Skip to main content
SpringerLink
Log in

Regorafenib: start low and go slow

  • Day-to-Day Practice
  • Published:
Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer, version 3. 2014

  2. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516

    Article  CAS  PubMed  Google Scholar 

  3. Kim DD, Eng C (2012) The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012:406830

    PubMed Central  PubMed  Google Scholar 

  4. Grothey A, Van Cutsem E, Sobrero A, CORRECT Study Group et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo- controlled, phase 3 trial. Lancet 381(9863):303–312

    Article  CAS  PubMed  Google Scholar 

  5. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G et al (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical anti- tumor activity. Int J Cancer 129:245–255

    Article  CAS  PubMed  Google Scholar 

  6. Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2(1):51–63

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Benson AB 3rd, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918–2926

    Article  CAS  PubMed  Google Scholar 

  8. Grothey A, George S, van Cutsem E, Blay J-Y, Sobrero A, Demetri GD (2014) Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist 19:669–680

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U et al (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–2667

    Article  CAS  PubMed  Google Scholar 

  10. Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H et al (2014) Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Investig New Drugs 32:104–112

    Article  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Faculty of Medicine, Hematology Oncology Department, Saint Joseph University, Beirut, Lebanon

    S. Tabchi & M. Ghosn

Authors
  1. S. Tabchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Ghosn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Tabchi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tabchi, S., Ghosn, M. Regorafenib: start low and go slow. Targ Oncol 10, 445–447 (2015). https://doi.org/10.1007/s11523-014-0352-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-014-0352-7

Keywords

Search

Navigation